1. Home
  2. SGU vs ZURA Comparison

SGU vs ZURA Comparison

Compare SGU & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGU

Star Group L.P.

HOLD

Current Price

$13.04

Market Cap

422.1M

ML Signal

HOLD

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$6.29

Market Cap

407.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGU
ZURA
Founded
1995
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
422.1M
407.0M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
SGU
ZURA
Price
$13.04
$6.29
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$11.78
AVG Volume (30 Days)
28.1K
353.1K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
5.67%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,784,418,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.70
N/A
Revenue Growth
1.04
N/A
52 Week Low
$11.31
$0.99
52 Week High
$13.75
$6.88

Technical Indicators

Market Signals
Indicator
SGU
ZURA
Relative Strength Index (RSI) 56.83 56.16
Support Level $12.66 $5.78
Resistance Level $13.05 $6.40
Average True Range (ATR) 0.31 0.47
MACD -0.05 -0.05
Stochastic Oscillator 41.09 45.74

Price Performance

Historical Comparison
SGU
ZURA

About SGU Star Group L.P.

Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Share on Social Networks: